BioCentury | Feb 18, 2020
Regulation

Regulatory Roundup: PharmaMar-Jazz, BioCryst products under FDA review; plus EU approvals of Vyndaqel, Beovu; and more

FDA is reviewing a pair of candidates to treat lung cancer and hereditary angioedema, while the European Commission has approved a new competitor for Eylea in wet AMD and expanded another drug's label to treat...
BioCentury | Jan 25, 2020
Targets & Mechanisms

CAR T strategies for cracking the code in solid tumors

As drug developers try to crack the code for making CAR T cell therapies work in solid tumors, they aren’t sticking to the playbook that led to success with other modalities. BioCentury’s analysis of the...
BioCentury | Jan 24, 2020
Preclinical News

Jan. 23 Preclinical Quick Takes: Metastasis-associated cancer-associated fibroblast populations; plus NIH-TeneoBio and Basilea

Cancer-associated fibroblast subsets linked to metastasis In a study published in Nature Communications , a team from Institut Curie and INSERM identified within breast cancer patients’ lymph nodes four subpopulations of cancer-associated fibroblasts (CAFs). Two subsets...
BioCentury | Oct 11, 2019
Targets & Mechanisms

CAR Ts can move well beyond cancer, but will need to go allogeneic first

Preclinical studies showing the utility of CAR T cells outside of cancer are ramping up, and developers have taken notice. But turning the modality into a general-purpose tool will require companies to break through safety...
BioCentury | Jul 11, 2019
Targets & Mechanisms

The tumor stroma rises as the newest source of immuno-oncology targets

With a spate of therapies entering the clinic, the next frontier in the fight against resistance to checkpoint inhibitors will be the stroma. The lead target marks a resurgence of interest in TGFβ, and behind...
BioCentury | Jun 27, 2019
Distillery Therapeutics

4-1BBL fusion protein boosts T cell bispecific Abs for gastric cancer and lymphoma

DISEASE CATEGORY: Cancer INDICATION: Gastric cancer; lymphoma Tumor-targeted 4-1BBL fusion proteins could enhance the efficacy of T cell bispecific antibodies to treat gastric cancer and lymphoma. The fusion proteins consist of a trimer of the...
BioCentury | Jun 22, 2019
Clinical News

June 21 Clinical Quick Takes: Melanoma miss for Exelixis/Genentech combo; plus Progenics, Turning Point, Gracell

Cotellic/Tecentriq combo misses in melanoma Exelixis Inc. (NASDAQ:EXEL) revealed in a Thursday SEC filing that Cotellic cobimetinib plus Tecentriq atezolizumab from partner Genentech Inc. missed the primary endpoint of improving progression-free survival vs. Keytruda pembrolizumab...
BioCentury | May 6, 2019
Company News

Pfizer's small molecule tafamidis approved for TTR amyloid cardiomyopathy

FDA approved two forms of Pfizer's tafamidis Monday well ahead of their PDUFA dates, making the therapies the first small molecules approved for the cardiomyopathy dominant form of transthyretin (TTR) amyloidosis in the U.S. The...
BioCentury | Apr 6, 2019
Finance

Big caps under pressure

Biogen’s fall in the wake of its decision to discontinue late-stage trials of Alzheimer’s therapy aducanumab is yet another reminder that large caps are in dire need of new pipeline products, and could serve as...
BioCentury | Mar 1, 2019
Financial News

Syncona leads CHF35M A round for Anaveon

Anaveon AG (Zurich, Switzerland) closed the first undisclosed tranche of a CHF35 million ($35 million) series A round on Feb. 26 to help bring its biologic IL-2 receptor agonists into the clinic. Syncona Ltd. (LSE:SYNC)...
Items per page:
1 - 10 of 271